N/A N=49 Feasibility Study for Development of an Early Test for Ovarian Failure
Healthy · Premature Ovarian Failure
Primary: Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels. — 50.7; 48.8; 96.6; 47.7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=232 Predictors of Ovarian Insufficiency in Young Breast Cancer Patients
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
Phase 3 N=19 Primary Ovarian Insufficiency: Phenotype and Optimal Treatment
Primary Ovarian Insufficiency
Primary: Change in Dual Energy X-ray Absorptiometry (DXA) Measure of Bone Mineral Density (BMD) of the Lumbar Spine — 0.228; 0.673 Z-score
Phase 2 N=59 GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
Amenorrhea · Premature Ovarian Failure · Ovarian Function Insufficiency
Primary: Number of Participants With Secondary Amenorrhea Following 3-month Depot Leuprolide — 37 participants
Phase 2 N=35 Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women
Cardiovascular Risk Reduction
Primary: Arterial Stiffness — 10.1; 14.8; 6.4; 12.7 mm Hg
Phase 3 N=39 LutrePulse Hypogonadotropic Hypogonadism
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120
Phase 3 N=257 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Breast Cancer · Infertility · Menopausal Symptoms
Primary: Rate of Premature Ovarian Failure at 2 Years — 15; 5 Participants
N/A N=20 Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure
Ovarian Failure, Premature
Primary: Estradiol — 53; 14; 12 pg/mL
Phase 2 N=41 Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women
Adult Idiopathic Generalized Osteoporosis
Primary: Change in Lumbar Spine Bone Mineral Density (LS-BMD) on Active Medication — 10.1; 4.1 percentage of change
Phase 4 N=442 Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)
Infertility
Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes
Early Phase 1 N=6 Investigation of Female Reproductive Hormone Dynamics During Adolescence
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants
Phase 4 N=226 Obesity, Oral Contraception, and Ovarian Suppression
Ovarian Suppression
Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants
Phase 3 N=249 Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
Phase 3 N=22 Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Menopause · Fracture · Osteoporosis
Primary: Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA) — 10.8 percentage of BMD change
Phase 3 N=24 Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)
PCOS
Primary: 17OHP Levels After hCG — 3.2; 1.3 ng/ml
Phase 1 N=34 Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects
Healthy
Primary: Baseline Corrected Area Under the Concentration-Time Curve From Zero to Last Quantifiable Concentration (AUC 0-t,Adj) for Follicle-Stimulating Hormone (FSH) — 3187.4…
Phase 2 N=33 Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
Adult Idiopathic Generalized Osteoporosis
Primary: Percent Change in Lumbar Spine Areal BMD by DXA — 5.2 percentage of change
Phase 3 N=3,066 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma
Primary: Disease-free Survival — 84.7; 86.6; 89 percentage of participants — p=0.1
Phase 2 N=31 Triptorelin for Ovary Protection in Childhood Onset Lupus
Systemic Lupus Erythematosus
Primary: Dose of Triptorelin for Ovarian Suppression — NA; 120 μg/kg
Phase 4 N=23 Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study
Infertility
Primary: Oocytes — 19; 47 oocytes
N/A N=34 Follicular Activation in Poor Responders
Infertility
Primary: Number of Metaphase II (MII) — 4; 2 Oocytes — p=0.302
Phase 2 N=10 Elagolix for Fertility Enhancement Clinical Trial
Endometriosis · Unexplained Infertility
Primary: Number of Live Births — 3; 1 live births
N/A N=29 Investigational Oocyte Cryopreservation for Medical and Non Medical Indications
Infertility, Female · Deferred Childbearing
Primary: Fertility Quality of Life Questionnaire Completed After One Year After Oocyte Cryopreservation for Non-medical Reasons — 9 Participants
N/A N=30 Aspiration of Limited Number of Follicles to Prevent Severe Ovarian Hyperstimulation Syndrome
Infertility
Primary: Number of Participants of Severe Ovarian Hyperstimulation Syndrome — 2; 11 participants
Phase 3 N=740 Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 64; 71; 70 percentage of participants
N/A N=204 Oocyte Cryopreservation Registry (HOPE Registry)
Oocyte Cryopreservation
Primary: Thawing Cycle Level Live Birth Rate — 12.4; 15.0; 13.6 % of oocytes thawed per cycle
Phase 3 N=345 Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity
Breast Cancer
Primary: Number of Participants With Premature Ovarian Insufficiency — 10; 38 Participants
N/A N=79 Evaluation of Ovarian Morphology and Function in Overweight Women During Weight Loss
Weight Loss · Anovulation · Amenorrhea
Primary: Change From Baseline Ovulatory/Menstrual Function — 12; 18 Participants
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
Phase 2 N=24 Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants